

bs-4561R**[Primary Antibody]****Bivalirudin Rabbit pAb**

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

— DATASHEET —**Host:** Rabbit**Isotype:** IgG**Clonality:** Polyclonal**Target:** Bivalirudin**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: Bivalirudin is a specific and reversible direct thrombin inhibitor (DTI). Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech *Hirudo medicinalis*). Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.

Applications: IHC-P (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**ICC/IF** (1:100-500)**ELISA** (1:5000-10000)**Reactivity:** (predicted: Hirudin)**Predicted
MW.:** 2.108 kDa**Subcellular
Location:** Secreted